US EditionGalapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation - Galapagos (NASDAQ:GLPG)
Galapagos plans to close multiple global sites and cut 365 jobs as part of a strategic shift to focus capital on unmet medical needs and transformative business development.
- On October 21, 2025, Galapagos NV announced it intends to wind down its cell therapy business and pursue new transformational business development transactions using available cash resources.
- Following a comprehensive strategic review, the Board of Galapagos NV approved the wind-down plan unanimously except for the two Directors appointed by Gilead who recused themselves.
- About 365 employees would be impacted, with site closures in Leiden, Basel, Princeton, Pittsburgh, and Shanghai, and costs of 100 million to 125 million euros plus restructuring of 150 million to 200 million euros through 2026.
- Galapagos said it would consider viable proposals for all or part of the cell therapy business, with the remaining organization repositioned at its Mechelen, Belgium headquarters, and Henry Gosebruch stated, `We have undertaken a thorough strategic review and sale process.`
- Subject to consultations with works councils in Belgium and the Netherlands, Galapagos will continue operating the cell therapy unit and provide an updated 2025 cash outlook in early November with forward-looking statements and risk disclaimers.
15 Articles
15 Articles
Galapagos to Wind Down Cell Therapy Business After Search for a Buyer Comes Up Empty
Non-binding offers for Galapagos’s cell therapies assets came mostly from financial investors, and none offered sufficient terms or financing to support the business, the company said. Galapagos’s exit from cell therapy work will lead to site closures in Europe, China, and the U.S. The post Galapagos to Wind Down Cell Therapy Business After Search for a Buyer Comes Up Empty appeared first on MedCity News.
Galapagos is discontinuing its cancer drug development program. The Dutch-Belgian pharmaceutical company says it will phase out the division responsible for developing cell therapy. This will almost certainly result in the closure of a development center in Leiden, among other locations. A total of 365 people work at research centers in Leiden, Basel, Princeton, Pittsburgh, and Shanghai. It is highly likely that they will all lose their jobs. Th…
Earlier this year, Galapagos announced its intention to become the global market leader in cell therapy. Ten months later, the company suddenly shut down completely, and 350 employees lost their jobs.
Globe Newswire
The Manila TimesGalapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable...
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
